What medicine is Rucaparib? Indications analysis

Rucaparib (Rucaparib) is an oral small molecule targeted drug that belongs to the PARP inhibitor family. The development of PARP inhibitors is an important breakthrough in the field of oncology in recent years, especially showing unique effects in the treatment of tumors related to DNA repair defects. Rucapanib inhibits the activity of poly ADP ribose polymerase (PARP), causing fatal cumulative damage in tumor cells during the repair of DNA single-strand breaks, eventually leading to cell apoptosis. This mechanism of action is called "synthetic lethality" and is particularly significant in patients with BRCA gene mutations.

The indications of rucapanib are mainly focused on ovarian cancer, fallopian tube cancer and primary peritoneal cancer, especially for patients who have relapsed after previous chemotherapy. In some countries and regions, it is also approved as maintenance therapy for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy. In addition, rucapanib has also shown potential in the treatment of prostate cancer, especially for patients with castration-resistant prostate cancer who have gene defects in the DNA repair pathway. Clinical trial results have shown that it can delay the progression of the disease, bringing new hope to patients with limited treatment options.

Different from traditional chemotherapy, rucapanib emphasizes the concept of precision medicine, and its use often relies on genetic testing results. In clinical practice, doctors usually evaluate whether the drug is suitable for use based on the patient's BRCA status or other homologous recombination repair deficiency (HRD) conditions. For eligible patients, rucapanib can not only extend progression-free survival, but also improve the level of individualization of treatment.

Overall, rucapanib is not only a simple anti-tumor drug, but also represents the direction of tumor treatment from broad-spectrum chemotherapy to precise targeting. With the advancement of multiple studies around the world, its scope of indications may be further expanded. In the future, rucapanib has potential application prospects in the treatment of various cancers related to DNA repair defects such as breast cancer and prostate cancer.

Reference materials:https://www.drugs.com/mtm/rucaparib.html